Andersen, Johanna B., Sharmin, Sifat, Lefort, Mathilde, Koch-Henriksen, Nils, Sellebjerg, Finn, Sørensen, Per Soelberg, Hilt Christensen, Claudia C., Rasmussen, Peter V., Jensen, Michael B., Frederiksen, Jette L., Bramow, Stephan, Mathiesen, Henrik K., Schreiber, Karen I., Horakova, Dana, Havrdova, Eva K., Alroughani, Read, Izquierdo, Guillermo, Eichau, Sara, Ozakbas, Serkan, Patti, Francesco, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, Jenette, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Skibina, O, Solaro, C, Karabudak, R, Wijmeersch, BV, Csepany, T, Spitaleri, D, Vucic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, Sèze, JD, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, JP, Marousset, A, Patry, I, Hankiewicz, K, Pottier, C, Maubeuge, N, Labeyrie, C, Nifle, C, Leray, E, Laplaud, DA, Butzkueven, H, Kalincik, T, Vukusic, S, Magyari, M. Elsevier; 2021. The effectiveness of natalizumab vs fingolimod - A comparison of international registry studies.

Kalincik, Tomas, Kubala Havrdova, Eva, Ozakbas, Serkan, Kappos, Ludwig, Kuhle, Jens, Terzi, Murat, Lechner-Scott, Jeanette, Boz, Cavit, Grand'maison, Francois, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Horakova, Dana, Granella, Franco, Trojano, M, Bergamaschi, R, Pucci, E, Turkoglu, R, McCombe, PA, Pesch, VV, Van Wijmeersch, B, Solaro, C, Ramo-Tello, C, Izquierdo, Guillermo, Slee, M, Alroughani, R, Yamout, B, Shaygannejad, V, Spitaleri, D, Sánchez-Menoyo, JL, Ampapa, R, Hodgkinson, S, Karabudak, R, Butler, E, Prat, Alexandre, Vucic, S, Jokubaitis, V, Spelman, T, Butzkueven, H, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Onofrj, Marco, Lugaresi, Alessandra. B M J Group; 2019. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.

Fambiatos, Adam, Jokubaitis, Vilija, Grand'Maison, Francois, Grammond, Pierre, Sola, Patricia, Ferraro, Diana, Alroughani, Raed, Terzi, Murat, Hupperts, Raymond, Boz, Cavit, Lechner-Scott, Jeannette, Pucci, Eugenio, Horakova, Dana, Bergamaschi, Roberto, Van Pesch, V, Ozakbas, S, Granella, F, Turkoglu, R, Iuliano, G, Spitaleri, D, McCombe, P, Solaro, C, Slee, M, Kubala Havrdova, Eva Kubala, Ampapa, R, Soysal, A, Petersen, T, Sanchez-Menoyo, JL, Verheul, F, Prevost, J, Sidhom, Y, Van Wijmeersch, B, Vucic, S, Cristiano, E, Trojano, Maria, Saladino, ML, Deri, N, Barnett, M, Olascoaga, J, Moore, F, Skibina, O, Gray, O, Fragoso, Y, Yamout, B, Shaw, C, Prat, Alexandre, Singhal, B, Shuey, N, Hodgkinson, S, Altintas, A, Al-Harbi, T, Csepany, T, Taylor, B, Hughes, J, Jun, J-K, van der Walt, A, Girard, Marc, Spelman, T, Butzkueven, H, Kalincik, T, Duquette, Pierre, Lugaresi, Alessandra, Izquierdo, Guillermo. Sage; 2020. Risk of secondary progressive multiple sclerosis: a longitudinal study.